- Home
- YXT vs IMUX Comparison
YXT vs IMUX Comparison
Compare YXT & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YXT
- IMUX
- Stock Information
- Founded
- YXT 2011
- IMUX 2016
- Country
- YXT China
- IMUX United States
- Employees
- YXT N/A
- IMUX N/A
- Industry
- YXT
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- YXT
- IMUX Health Care
- Exchange
- YXT NYSE
- IMUX Nasdaq
- Market Cap
- YXT 102.1M
- IMUX 90.3M
- IPO Year
- YXT 2024
- IMUX N/A
- Fundamental
- Price
- YXT $0.66
- IMUX $1.01
- Analyst Decision
- YXT
- IMUX Strong Buy
- Analyst Count
- YXT 0
- IMUX 6
- Target Price
- YXT N/A
- IMUX $13.20
- AVG Volume (30 Days)
- YXT 33.6K
- IMUX 677.2K
- Earning Date
- YXT 05-21-2025
- IMUX 05-07-2025
- Dividend Yield
- YXT N/A
- IMUX N/A
- EPS Growth
- YXT N/A
- IMUX N/A
- EPS
- YXT N/A
- IMUX N/A
- Revenue
- YXT $45,374,087.00
- IMUX N/A
- Revenue This Year
- YXT N/A
- IMUX N/A
- Revenue Next Year
- YXT N/A
- IMUX N/A
- P/E Ratio
- YXT $1.24
- IMUX N/A
- Revenue Growth
- YXT N/A
- IMUX N/A
- 52 Week Low
- YXT $0.69
- IMUX $0.83
- 52 Week High
- YXT $11.00
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- YXT N/A
- IMUX 50.45
- Support Level
- YXT N/A
- IMUX $0.86
- Resistance Level
- YXT N/A
- IMUX $1.01
- Average True Range (ATR)
- YXT 0.00
- IMUX 0.08
- MACD
- YXT 0.00
- IMUX 0.01
- Stochastic Oscillator
- YXT 0.00
- IMUX 76.74
About YXT YXT.COM GROUP HOLDING LIMITED SPON ADS EA REP 3 CL A SHS
Yxt.Com Group Holding Ltd operates as a technology company. The company has created a SaaS model that integrates software and content, assisting customers in the digital transformation of corporate learning. The company operates in the People's Republic of China.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.